AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.2 USD | +0.16% | -0.40% | +506.69% |
02/04 | North American Morning Briefing : Stocks Seen -2- | DJ |
01/04 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
160.4 USD | -1.29% | -0.79% | 287B | ||
22.2 USD | +0.16% | -0.40% | 69.3M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+506.69% | 69.3M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.